Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.09 | N/A | -87.50% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.09 | N/A | -87.50% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook without offering specific guidance. They emphasized their commitment to ongoing projects.
Management did not provide specific guidance for future quarters.
The company is focusing on its ongoing projects and pipeline.
Nektar Therapeutics reported a loss that was worse than expected, but the stock still rose by 0.4%. This increase may reflect investor optimism about the company's ongoing projects despite the lack of specific guidance. The market seems to be taking a wait-and-see approach as the company continues to navigate its pipeline.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CONSOLIDATED EDISON
Nov 1, 2010